Print Page   |   Sign In   |   Join ISSX
ISSX News: General

4th Annual Conference of India (SSX-2019)

Tuesday, November 19, 2019   (0 Comments)
Posted by: ISSX
Share |

4th Annual Conference of India (SSX-2019)

Indian Society for the Study of Xenobiotics (SSX-India) organized the 4th Annual Conference at J.N. Tata Auditorium, Indian Institute of Science (IISc), Bangalore, from September 18-21, 2019, with the theme “Exploring Impact of ADMET and Modelling Science and Technology on Drug Discovery and Development.” 

SSX India is consistently growing and has had great success in the last four years. The number of participants increased from previous years, with 356 participants this year. It was a balanced blend of delegates from academia and industry.
 
Key features of the conference included: pre-conference workshops and short-courses, main conference with two plenary lectures and seven sessions across three days, panel discussion for students, poster sessions, oral presentations by young investigators, a cultural program, a mentorship program, and travel grants to national and international students. There were 20 scientific talks by speakers from academia and industry, five sponsor talks, and young investigator presentations from the top five abstracts.

Pre-conference workshop and short-course:
Three parallel sessions:
1. Short-course: Drug Metabolism, Transporters and Toxicology

2. Hands-on Workshop: Pharmaceutical Modelling and Simulation (PuMAS) Software

3. Micro Sampling and Mass Spectrometry Workshop

Main objectives of the pre-conference workshop/short-course were:
a) to provide basic knowledge of ADMET concepts to the students/young scientists to prepare them for better understanding of the content of the main conference and

b) to provide hands-on experience with PuMAS software and mass spectrometer and their utility

One-hundred and twenty delegates participated in the pre-conference workshop and short-course.

Drug Metabolism, Transporters and Toxicology: Sixty-five delegates attended this session, which had four lectures. Dr. Krishna Iyer, Bombay College of Pharmacy, India, kicked off the session with “Introduction to Metabolism: Phase I, II Reactions (focused on reaction mechanisms).” Dr. Mike Sinz, of BMS, Princeton, USA, gave the second lecture, “Drug-Drug Interactions – Basic concepts and Assessment.” Dr. Bhagwat Prasad, Washington State University, USA, presented “Introduction to Drug Transporters and their Role in Drug Disposition.” Dr. Myrtle Davis, BMS, Princeton, USA, presented “Basic Concepts of Toxicology” following this. 

PuMAS Workshop: Dr. Vijay Ivaturi, University of Maryland, USA, and Dr. Surulivel Rajan, Manipal University, Manipal, conducted this workshop, which 37 delegated attended. Dr. Ivaturi demonstrated role and use of PuMAS software. Participants performed analysis in real-time with provided case studies. This was widely appreciated, especially by those with specific interest in the area. Many participants showed interest in the upcoming workshop, which will be conducted in various cities across India.

Mass Spectrometry Workshop: Mr. Mallikarjun at Dr. Utpal Tatu’s laboratory at IISc, Bangalore conducted this workshop. Dr. Prashant Kole and Ms. Priyadeep Bhutani, BBRC, Syngene International Ltd. India, explained micro sampling and LC-MS/MS. About 20 delegates attended. The workshop introduced micro sampling procedures, including sample handling, sampling volume, spotting technique, sample storage, and transfer, to participants. Participants became familiar with the hardware and software (data acquisition and processing) in a mass spectrometer. The discussions covered calibration, sample preparation, and method development for test compounds using LC/MS. Analysis and interpretation of data acquired on test compounds followed this.

Main conference (19th – 21st September 2019)

The main conference day started with opening remarks by Dr. T. Thanga Mariappan, SSX President, explaining the vision of SSX and reflecting on SSX 2019. He spoke about the history of SSX and spoke about the theme of the conference. Dr. Mariappan explained two new, student-focused initiatives of SSX, which include the certificate course on DMPK for students and the hands-on workshop on PuMAS software that will be held in Bangalore, Delhi, and Hyderabad during February and March of 2020. He announced that the 7th Asia Pacific ISSX will be hosted by SSX-India in Bangalore, February 21-24, 2021. 

Conference Inauguration with Indian Rituals:
Dr. Lois-Lehman-McKeeman, Prof. Yuichi Sugiyama, Dr. Bill Smith, Dr. Jasminder Sahi, and Dr. T. Thanga Mariappan inaugurated the conference with the traditional lamp lighting ceremony. All ceremonial dignitaries wore traditional attire to give it an Indian touch. 


Review summaries of the short courses, plenary lectures, parallel sessions, and poster presentations on the ISSX website at www.issx.org/ssxindia19.  

Plenary Lecture 1:
The scientific session started with a plenary lecture, “Quantitative prediction of the hepatic clearance and complex drug interactions using extended clearance concept and PBPK with in vitro transporter/enzyme data,” by Professor Yuichi Sugiyama, RIKEN institute, Japan. Dr. Jasminder Sahi, Sanofi, China moderated the session. Dr. Sugiyama described the importance of transporters in drug disposition, emphasizing the need for transporters and use of extended clearance in regulating tissue exposure. He explained the use of coproporphyrin-I as an endogenous biomarker to predict OATP-mediated DDIs prior to conducting a clinical trial.

Session 1: Drug Metabolism and DDI
Dr. Bill Smith, Gilead, USA, and Dr. Rama Sivasubramanian, Novartis, India, moderated the first session of the main conference. Experts discussed the following topics:

1. Solving Biotransformation Challenges – Beyond P450 Enzymes (Dr. Cyrus Khojasteh, Genentech, USA): Dr. Khojasteh began by emphasizing the diverse chemical properties of small molecule drugs currently in the market. He then moved the narrative to the importance of drug metabolizing enzymes in early drug development. After introducing the CYP enzymes, he moved onto non-CYP pathways. Examples from Genentech and literature on unusual reactions by FMO, AOX were discussed. Additionally, rodent PK studies were used to understand the importance of these unusual pathways on clearance/drug disposition. He discussed an interesting case study on the challenges regarding the use of Carfilzomib as payload to ADCs. Dr. Khojasteh stressed detailed characterization on interactions of thioredoxin and glutaredoxin to disulfidic bonds on the payload and the effect on overall activity.

2. Drug Metabolism (and transport) in the Eye (Dr. Upendra Argikar Novartis, USA): Dr. Upendra briefly introduced the role of ADMET in drug discovery and development. He focused on the unmet need of drugs in treatment of ocular diseases and the challenges discovery scientists face. He presented a case study on ocular metabolism of levobunolol that indicated how different it is compared to liver metabolism. He emphasized the importance of understanding metabolic enzymes and transporters in the ocular region to improve exposure and efficacy of topically used drugs. 

3. The Constitutive Androstane Receptor (CAR) and Enzyme Induction (Dr. Mike Sinz Bristol-Myers Squibb, USA): Dr. Sinz introduced enzyme induction by a different nuclear hormone receptor and its effect on drug disposition. Then, he focused on the unique properties of CAR, CAR’s mechanisms of activation, gene targets, and cross-talk with PXR, the induction of CYP3A enzymes, and differences in in vitro and in vivo enzyme induction via CAR activation among species.

4. Transporters in Safety and Discovery (Roelof de Wilde, Solvo Biotechnology, Hungary): Dr. de Wilde explained the importance of transporters in different aspects of drug disposition including DDI, drug accumulation and toxicity, drug-induced cholestasis, and renal toxicity. He touched on different, complex liver models, such as HepatoPac, to understand drug disposition. He emphasized how SOLVO is helping to improve knowledge by providing cutting-edge models and technologies.

5. ADME driven clinical candidate optimization in integrated drug discovery: Case study (Dr. Vishwottam Kandikere, Syngene International Ltd., India): Dr. Kandikere introduced the Syngene facilities, which support integrated drug discovery. He presented an investigative case study about the development of dosing methodology for buccal drug delivery in mice. He explained the pharmacokinetic approach they used, which ultimately helped to screen candidates in discovery project and lead to optimization.

Session 2: Drug Transporters and Disposition
Dr. Yuichi Sugiyama, RIKEN, Japan, and Dr. Sagnik Chatterjee, BBRC, Syngene International Ltd., India, moderated this session. Experts discussed the following topics: 
1. Confidence in translation: A case study of a complex human PK prediction of an integrin antagonist (Dr Bill Smith, Gilead): Dr. Smith explained PK and dose prediction of valategrast acid, an OATP substrate, using extended clearance and PBPK model. This example illustrated the power of PBPK models for processes (enterohepatic circulation) that may remain undetected in conventional in vitro assays. 
2. Interplay of efflux transport and metabolism: Is one more important than another in enterohepatic recycling of drugs? (Dr Bhagwat Prasad, Washington State University): Dr. Prasad explained the importance of considering enterohepatic circulation with testosterone. He demonstrated that phase II metabolizing enzymes and transporters impact enterohepatic circulation.
3. D Spheroid Models for in vitro Toxicity Testing (Dr. Roxana Ghadessy, Corning Life Sciences): Dr. Ghadessy described the use of 3D spheroids in hepatotoxicity, cardiotoxicity, and neurotoxicity models.
4. Characterization of hepatobiliary transport of a bile acid and organic anions in vitro to identify the rate-determining process: Use of doubly transfected cell line systems (Dr. Sumito Ito, Genomembrane, Japan): Dr. Ito explained that double transfected cell systems with an uptake and efflux transporter can be used to understand disposition and accumulation of endo- and exogenous compounds.
5. Sponsor Talk: Microflow Data Update and Overview of the Echo MS System (Rolf Kern, AB Sciex): Rolf Kern introduced Echo MS, the first mass spectrometry system based on Acoustic Droplet Ejection sampling technology, to the audience in his Sponsors Talk. He gave a few examples that show a minimal matrix factor with this technology, which leads to easy and cost effective sample clean up.

Plenary Lecture 2: 
The second day began with a plenary lecture by Dr. Lois Lehman-McKeeman, BMS, USA, and was moderated by Dr. Sandhya Mandlekar, BBRC, India. Her topic for the lecture was “Toxicology in Drug Discovery and Development: Methods, Models and Mechanisms.” She emphasized the need for scientists to employ various tools from cell cultures to in vivo models based on the questions at hand.

Session 3: Toxicological Issues Encountered in Drug Discovery and Development
Session 3, which was sponsored by GVK Bio-sciences, Hyderabad, India, followed the plenary lecture. Dr. Lois Lehman-McKeeman, BMS, USA, and Dr. Anandi Karumbati, CCBT, inStem, India, moderated the session. Toxicological issues were introduced for the first time at SSX 2019. Experts discussed the following topics:

1. Ecotoxicological Modelling of Contaminants of Emerging Concern (CECs) Using Quantitative Structure-Activity Relationship (QSAR) Approaches: A Few Case Studies (Kunal Roy, Jadavpur University, India): Dr. Kunal Roy presented the role of computational modelling in eco-toxicity endpoints of CECs along with risk management. He discussed how these pharmaceuticals can be biomagnified from aquatic organisms to humans. Finally, he discussed how QSAR modelling, along with the green chemistry principles, could be used to design less hazardous and possibly non-toxic chemicals to reduce environmental risks.
2. The next talk was by Dr. Kesava Cuddapah, Curio Biotech, Switzerland. He mentioned the full range of services offered by Curio from discovery to human clinical trials. In particular, with respect to toxicity assessment of APIs, he explained various resources available, including cell lines and primary human cells derived disease models (co-cultures), especially the DART assay.
3. Xenobiotic compounds: How it modifies glucose milieu? (Dr. Subbiah Ramasamy, Professor, Madurai Kamaraj University): Dr. Ramasamy presented two case studies, the first of which discussed association between organophosphate exposure and diabetes. He expressed that chronic organophosphate exposure functionally modulates the gut microbiome and induces glucose intolerance via gluconeogenesis. In the second study, he discussed how regular consumption of 4-methyl imidazole, a food additive, through eatables, elevates insulin-mediated lipid synthesis and increases the risk of pancreatic cancer.
4. Drug Polymorphism: Impact on Pharmacokinetics (Dr. Pratima Srivastava, GVK Bioscience ): Dr. Srivastava explained how the same dose of different batches of compound showed different effects in in vivo studies. This discrepancy was better understood after XRD studies revealed the presence of polymorphs, which emphasized the need for more stringency when scaling up to in vivo studies like same route/solvent and analysis for presence of polymorphs.

Session 4: Modelling and Simulation
Two parallel sessions (sessions 4 and 5) were organized in the afternoon of day two. Dr. Surulivel Rajan, Manipal University, India, and Dr. Manasa Deepa, East West College of Pharmacy, Bangalore, India, moderated session 4, Modelling and Simulation. In this session, three speakers shared their expertise and experience in the field. 

Dr. Rabi Sankar Bhatta, Senior Scientist, CSIR-CDRI, India, presented “Pharmacokinetic guided drug discovery and development” in this session. He introduced the role of pharmacokinetics in new drug discovery and explained the difference between in vitro biological active compounds and in vivo ineffective NCEs due to poor pharmacokinetic properties. In his presentation, he discussed the pharmacokinetic profile of new drugs with case studies and pharmacokinetic guided strategies in new discovery, attrition, reduction, and enhancement of the efficacy of NCE.

Dr. Jan Wahlstrom, Amgen, USA, presented “Drug Metabolites as inhibitors: Translation to the Clinic Using Modelling and Simulation.” His presentation focused on integrating in vitro, pre-clinical, and clinical data to develop quantitative predictions for DDIs due to metabolite-mediated inhibition or inactivation. He explained that quantitative prediction of the magnitude of DDI is critical to underwriting patient safety in the clinical setting. He also explained how PBPK modelling can assist in reasonable prediction of DDI magnitude, including complex scenarios such as inhibitory metabolites, which will help patient safety in the clinical setting.

Dr. Vijay Ivaturi, University of Maryland, USA, presented the final talk, “Pharmacometrics as a decision-making toolkit in drug development and clinical therapeutics.” He touched on the fundamental ideas and concepts of pharmacometrics, which illustrated success stories in pharmaceutical drug development and clinical therapeutics. He focused on MID3 approaches, which FDA and EMA adopted, to improve the implementation, standardization, and acceptance of this approach in generic drug development and regulatory review.

Session 5: New Tools/Technologies
Dr. Vamsi Madugula, Syngene International Ltd., India, and Dr. Amol Raje, Eurofins, Bangalore, moderated session 5. Dr. Albert Li , In vitro ADMET Laboratories, USA, delivered “Novel hepatic and enteric experimental systems for the evaluation of drug metabolism, drug-drug interactions, and drug toxicity.” Dr. Li talked about the novel hepatic and enteric technologies that developed in his lab. He summarized the use of permeabilized cofactor supplemented cryopreserved human hepatocytes (MetMax human hepatocytes) in phenotyping of metabolic pathways, CYP450 inhibition, and activating and detoxifying pathways. He also presented the data generated with cryopreserved human enterocytes and intestinal mucosal experimental systems for the evaluation of enteric drug metabolism, drug-drug interactions at gut level, and enteric toxicity. 

Dr. Ashwani Sharma, Biopredic International, France, delivered the second talk, “HepaRG®: In vitro tool to study drug metabolism and hepatotoxicity in the pharmaceutical industry.” Dr. Sharma mentioned that HepaRG® is a highly reproducible cell line, without the donor variability seen in PHH, and ensures a consistent and stable assay system. The cell line expresses liver-specific genes like CYP enzymes, transporter proteins at levels similar to PHH, and shows the difference from other liver cell lines such as HepG2 and HuH7. Cholestatic drugs can be identified in HepaRG® cells by measuring their effect on bile acid efflux. HepaRG® cells exhibit features that make them as useful as an in vitro model for drug metabolism, disposition, and toxicity studies, as described in FDA 2006 and OECD 2014 guidelines, and can replace the requirement for primary human hepatocytes. 

The session concluded with Dr. Joan Eilstein’s presentation. He delivered a talk titled “Characterization of metabolizing enzymes in human skin and reconstructed human skin models from SkinEthicTM.” He explained that skin is considered one of the main extra-hepatic metabolizing organs. Dr. Eilstein developed a reconstructed human skin 3D model and compared it to excised human skin (EHS). Dr. Eilstein presented the comparative data of expression of mRNA’s of several drug-metabolizing enzymes (CYP450 and non-CYP), transporters, and their apparent catalytic parameters in skin model and EHS. The results indicate that skin models can substitute EHS for selecting cosmetic ingredients based on their metabolism, efficacy, and safety.

Session 6: Special Session for Students 
This session aimed to help students understand career prospects and demonstrate how they can prepare themselves to become drug discovery and development professionals. Dr. Arti Thakkar, Amity University, India, and Mr. Anoop Kumar, BBRC, Syngene International Ltd., India, moderated the session, which was divided into three parts: lecture, student panel discussion, and cultural program.

Professor Ramesh Goyal, Vice-Chancellor, DPSRU, Delhi, began the session with an inspirational talk, titled “New Drug Discovery & Development in the Era of 4th Industrial Revolution: Excitement, Opportunities and Challenges.” He emphasized newer technologies in alignment with traditional, herbal medicines and spoke about his own research experience in developing a new chemical entity from a single herbal plant. 

The panel comprised a diverse blend of panellists from Indian and US academic and industry settings. Dr. Bill Smith (Gilead Sciences, USA), Dr. Manjunath Ramarao (BBRC at BMS, Bangalore, India), Prof. Krishna Iyer (Bombay College of Pharmacy, India), and Dr. Bhagwat Prasad (Washington State University, USA) served as panellist. Ms. Anisha Das (NIPER, Mohali, India), Mrs. Athira Nair (Manipal College, India), and Ms. Safala Malvankar, (BBRC, Syngene International Ltd., India) were student representatives. Moderators for the panel discussion included Dr. Arti Thakkar (Amity University, India) and Dr. Sandhya Subash (BBRC, Syngene International Ltd., India). Panel members provided insightful perspectives to answer several thought provoking questions. The topics covered included: 

• How are students seeking advice and who are they approaching in the field of Drug Discovery and Development (DDD)
• How students/new investigators choose between various fields of DDD and how to prepare a back-up plan 
• How should young scientists make themselves stand out among their peers during interviews/on the job
• Experience of young investigators who recently started their career 
• Impact of current trends in the area of DDD on job opportunities and challenges in next 2-5 years


Cultural Program by Students
Dr. Manasa Deepa, East West College of Pharmacy, and Hari Kangne, BBRC, Syngene International Ltd., India, organized the cultural program. The event consisted of games, in which delegates were selected to perform a random task on stage. Further, students of East West College of Pharmacy organized a short and high-energy event highlighting local talent. Students presented various Indian dance forms. The program concluded with a DJ and many of the speakers, organizers, sponsors, and delegates danced on the stage.


Session 7: Case Studies in Drug Discovery
On the day 3 of the main conference, Dr. Jasminder Sahi, Sanofi, China, and Dr. Vinay HK, BBRC, Syngene International Ltd., India, moderated a thought provoking session, “Case Studies in Drug Discovery.” 

Dr. Narayanan Surendran from RythRx Therapeutics, USA, presented “When you come to a fork in the road, take it - my experiences as a DMPK scientist turned entrepreneur” first. He emphasized that ADMET concepts can be used to identify new product opportunities to meet patient requirements. He gave examples in the areas of transfusion medicine and new drug delivery technology for repositioning approved agents for certain unmet needs. 

Dr. Jasminder Sahi, Sanofi R&D, China, discussed regulatory clinical case studies in the second presentation. In her presentation, which elicited many interesting questions from the audience, she gave a brief introduction on transporters relevant to drug development and decision trees used in evaluating transporter-mediated drug interactions in clinic. In her example with teriflunomide, it was observed that increase in systemic exposure of the substrate would be much higher with combined inhibition of BCRP and OATP than is expected from inhibiting individual transporters with the perpetrator. She also discussed the effect of 2D6 polymorphism and transporter interactions.

In the next presentation, Dr. Raju Subramanian, Gilead Sciences, USA, presented “Phase-I journey of GS-6207: A Novel, Potent and Selective First-In-Class Inhibitor of HIV1 Capsid Function Displays Long Acting Pharmacokinetics and Antiviral Activity in Human.” He presented Phase-I clinical pharmacokinetic data and anti-viral activity of GS-6207. The compound was highly potent and showed very long half-life, which is intended to help patients avoid the burden of daily dosing. Due to the long half life, he shared that there would be challenges in conducting further mechanistic studies like drug-drug interaction experiments. 

The next presentation was from Dr. Bala Subramanian, Bugworks Research, India, titled “Discovery of a novel antibacterial agent to combat antimicrobial resistance.” He recognized anti-microbial resistance as a global emergency and discussed how his team developed first-in-class compounds, which are effective on resistant bacterial strains. He shared the preclinical efficacy, pharmacokinetic, and safety data of the compound, which will enable clinical development of GS-6207 in 2020.

Poster session: 
Eighty abstracts were selected out of the 88 that were received for the poster sessions. Various Drug Discovery and Development topics included: (i) Pharmacokinetic, Metabolism, Disposition, DDI and Transporters; (ii) Modelling, simulation and PBPK; (iii) QSAR and other modelling approaches; (iv) Chemistry, Pharmacology and Toxicology; (v) Formulation Development and (vi) Bioanalysis and Met-ID. The committee selected 21 abstracts for poster presentation competition and they selected the five best for young investigators presentations and speaker presentations. A panel of judges from industry and academia evaluated the posters over first two days of the main conference, and they award the three best posters with certificates and cash prizes. Two different organizations shared second place and two individual researchers from the same group shared first place. The winners of the poster sessions were:

First Position:
(i) Aishwarya R from Department of Pharmaceutics, Faculty of Pharmacy, M.S.Ramaiah University of Applied Sciences, Bangalore, India
PHARMACOLOGICAL STUDIES OF BISPHOSPHONATE PER ORAL DELIVERY IN THE TREATMENT OF OSTEOPOROSIS INDUCED RAT MODEL

(ii) Kalyani A from Department of Pharmaceutics, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangalore, India
IN SILICO DOCKING ANALYSIS OF CONJUGATED BISPHOSPHONATE HYDROXYAPETITE WITH RANKL/OPG COMPLEX AND MELVONATE PATHWAY ENZYMES FOR ANTI-OSTEOPOROTIC ACTIVITY

Second Position:
(i) Anisha Das from Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar 160062, Punjab.
UNDERSTANDING THE ROLE OF RENAL TRANSPORTERS IN THE DISPOSITION OF ACYCLOVIR IN HEALTHY AND RENAL IMPAIRED POPULATIONS

(ii) Shweta Sharma and Anusmrithi U. Sharma (equally contributing authors) from *Indian Institute of Integrative Medicine, Jammu, India and #Center for Chemical Biology and Therapeutics, Institute for Stem Cell Science and Regenerative medicine, Bangalore, India
PROTEIN-PROTEIN INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR POTENTIAL THERAPEUTIC INTERVENTION: IDENTIFICATION AND VALIDATION

Third Position: 
Veerapandian Sureshkumar from Dept. of Veterinary Pharmacology and Toxicology, Veterinary College and Research Institute, Tamil Nadu Veterinary and Animal Sciences University, Tirunelveli, 627 358, India
DETECTION OF ENROFLOXACIN IN POULTRY DROPPINGS BY A VALIDATED HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY-FLUORESCENT DENSITOMETRY METHOD

Young Investigator Presentation: 
The five best abstracts were selected for the Oral Presentation by young/student research scholars. Aarzoo Thakur (NIPER-Mohali, India); Mohammed Riyazuddin (CDRI, Lucknow, India); Ji Eun Park (Sugiyama laboratory, RIKEN, Japan); Sumedha SK (M.S.Ramaiah University of Applied Sciences, India) and Moumita Dhara (Jadavpur University, Kolkata, India) presented. Young scientists presented their research to a diverse audience and received constructive feedback to help better their research careers. Judges evaluated the five presentations and awarded a certificate and cash prize to the two best presenters. The following were the winners for Oral Presentation:

First Position: Ji Eun Park from Sugiyama laboratory, RIKEN, Japan 
MECHANISM-BASED PBPK MODELLING OF PEMAFIBRATE TO DESCRIBE DRUG-DRUG INTERACTIONS WITH CYCLOSPORINE AND RIFAMPICIN

Second PositionAarzoo Thakur from NIPER-Mohali, India 
PREDICTIVE ANALYSIS OF THE INTESTINAL BIOAVAILABILITY USING IN-HOUSE BUILT MECHANISTIC ORAL ABSORPTION MODEL

Travel Grant: 
The 48 students, who presented posters and travelled from outside Bangalore, were provided the partial travel grant to attend the conference. 

Mentorship program:
SSX started a mentorship program this year to provide early career support to student members. Students enrolled in the program at the time of registration and provided their area of interest, subject of research, and intended career plan. Based on their research interest, students were assigned to mentors who were either esteemed speakers of the conference or senior scientists from industry or academia. Thirty students were assigned to eighteen the mentors that kindly accepted the opportunity to participate in the program.

Meeting Chair:
T. Thanga Mariappan, Ph.D., 
President, SSX, India
Senior Lead Investigator, Biocon-BMS R&D Centre (BBRC), 
Syngene International Ltd., Bangalore, India.

Meeting Co-Chair:
Vinay H.K., Ph.D. Secretary, SSX, India
Lead Investigator, Biocon - BMS R&D Center (BBRC),
Syngene International Ltd., Bangalore, India.

Meeting Organizing committee:
Deepika Dhaware (BBRC/Syngene)
Vamsi Madgula (Syngene)
Jasminder Sahi (Sanofi, China)
Bhagwat Prasad (Univ. Washington)
Sandhya Mandlekar (BMS, India)
Amarjeet G (BBRC/Syngene)
Anoop Kumar (BBRC/Syngene)
Arti Thakkar (Amity University 
Anandi Karumbati (CCBT, InStem)
Sankar Sivaprasad (BBRC/Syngene)
Shashyendra Singh (BBRC/Syngene)
Vishwanath Kurawattimath (BBRC/Syngene)
Sagnik Chatterjee (BBRC/Syngene)
Priyadeep Bhutani (BBRC/Syngene)
Uday Agarwal (BBRC/Syngene)
Manasa Deepa (East West College of Pharmacy)
Nilesh Gaud (BBRC/Syngene)
Sachin Tulsankar (BBRC/Syngene)
Anup Deshpande (BBRC/Syngene)
Sandhya Subash (BBRC/Syngene)
Eljo J. Jose (BBRC/Syngene)
Satheesh Kumar (NIPER, Hyderabad)
S. Bharath (M.S. Ramaiah University)
Eljo Jose (BBRC/Syngene)
Ashwani Sharma (Biopredic)
Hari Kangne (BBRC/Syngene)
Mallikarjuna Rao (IISc)
Ramasivasubramanian (Novartis, Hyderabad)
Ravindra Reddy (BBRc/Syngene)
Sachin Tulsankar (BBRC/Syngene)
Safala Malvankar (BBRC/Syngene)
Sakthi Devan (BBRC/Syngene)

Meeting Sponsors/Collaborators:
Bristol-Myers Squibb
GVK Bio 
GenoMembrane
Amgen
Syngene
Solvo
AB Sciex
Biopredic-Advancells
Corning
Gilead
Samitek Instruments
ATNT Bugworks, Bangalore
In vitro ADMET
Allied biosystems
Nanotemper Tech
Vishnu Traders
Wipro GE Healthcare Pvt. Ltd.
Association of Pharmaceutical Teachers of India 
Orchid Scientific & Innovative India Pvt. Ltd.
East West College of Pharmacy 
Indian Institute of Science
M.S. Ramaiah University of Applied Sciences


Ongoing and Future Events of SSX-India:
• Certification Course of DMPK, August to December, 2019: To provide basic understanding of DMPK concepts, techniques and applications of preclinical to clinical translation; Webinar based training programme for 36 hours over 5 months in 5 premium pharmaceutical institutions
• Workshop on Physiology based Pharmacokinetic (PBPK) Models for Drug Development and Therapeutics: Jointly organized with Manipal College of Pharmaceutical Sciences on 21st and 22nd November, 2019 at Manipal Academy of Higher Education
• PuMAS Workshops, February and March, 2020: Hands-on workshop on PuMAS software in different cities of India (Amity University-Delhi; Manipal University-Manipal; MS Ramaiah University of Applied Sciences-Bangalore and NIPER-Hyderabad)
• Asia Pacific ISSX Meeting, 21st – 24th February, 2021: 7th AP-ISSX has been scheduled in February 2021 at Bangalore, India

 

Association Management Software Powered by YourMembership  ::  Legal